Lifeward Ltd. (LFWD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Lifeward Ltd. Do?
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel. Lifeward Ltd. (LFWD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Lawrence J. Jasinski and employs approximately 60 people, headquartered in YOKNEAM ILIT, Massachusetts. With a market capitalization of $26M, LFWD is one of the notable companies in the Healthcare sector.
Lifeward Ltd. (LFWD) Stock Rating — Reduce (April 2026)
As of April 2026, Lifeward Ltd. receives a Reduce rating with a composite score of 33.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LFWD ranks #3,036 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lifeward Ltd. ranks #442 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
LFWD Stock Price and 52-Week Range
Lifeward Ltd. (LFWD) currently trades at $6.57. The stock lost $0.05 (0.8%) in the most recent trading session. The 52-week high for LFWD is $7.57, which means the stock is currently trading -13.2% from its annual peak. The 52-week low is $0.35, putting the stock 1777.1% above its annual trough. Recent trading volume was 4K shares, suggesting relatively thin trading activity.
Is LFWD Overvalued or Undervalued? — Valuation Analysis
Lifeward Ltd. (LFWD) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.96x, versus the sector average of 2.75x. The price-to-sales ratio is 1.08x, compared to 1.66x for the average Healthcare stock.
At current multiples, Lifeward Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Lifeward Ltd. Profitability — ROE, Margins, and Quality Score
Lifeward Ltd. (LFWD) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -209.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -77.1% versus the sector average of -33.1%.
On a margin basis, Lifeward Ltd. reports gross margins of 41.5%, compared to 71.5% for the sector. The operating margin is -78.4% (sector: -66.1%). Net profit margin stands at -78.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -7.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
LFWD Debt, Balance Sheet, and Financial Health
Lifeward Ltd. has a debt-to-equity ratio of 172.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.31x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $2M.
LFWD has a beta of 3.29, meaning it is more volatile than the broader market — a $10,000 investment in LFWD would be expected to move 229.4% more than the S&P 500 on any given day. The stability factor score for Lifeward Ltd. is 9/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Lifeward Ltd. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Lifeward Ltd. reported revenue of $23M and earnings per share (EPS) of $-17.16. Net income for the quarter was $-18M. Gross margin was 41.5%. Operating income came in at $-18M.
In FY 2025, Lifeward Ltd. reported revenue of $22M and earnings per share (EPS) of $-17.16. Net income for the quarter was $20M. Gross margin was 38.3%. Revenue grew -14.1% year-over-year compared to FY 2024. Operating income came in at $-20M.
In Q3 2025, Lifeward Ltd. reported revenue of $6M and earnings per share (EPS) of $-0.20. Net income for the quarter was $-3M. Gross margin was 43.7%. Revenue grew 1.1% year-over-year compared to Q3 2024. Operating income came in at $-3M.
In Q2 2025, Lifeward Ltd. reported revenue of $6M and earnings per share (EPS) of $-0.58. Net income for the quarter was $-7M. Gross margin was 43.9%. Revenue grew -14.7% year-over-year compared to Q2 2024. Operating income came in at $-7M.
Over the past 8 quarters, Lifeward Ltd. has demonstrated a growth trajectory, with revenue expanding from $7M to $23M. Investors analyzing LFWD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
LFWD Dividend Yield and Income Analysis
Lifeward Ltd. (LFWD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
LFWD Momentum and Technical Analysis Profile
Lifeward Ltd. (LFWD) has a momentum factor score of 79/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 29/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
LFWD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Lifeward Ltd. (LFWD) ranks #442 out of 838 stocks based on the Blank Capital composite score. This places LFWD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing LFWD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LFWD vs S&P 500 (SPY) comparison to assess how Lifeward Ltd. stacks up against the broader market across all factor dimensions.
LFWD Next Earnings Date
No upcoming earnings date has been announced for Lifeward Ltd. (LFWD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy LFWD? — Investment Thesis Summary
The quantitative profile for Lifeward Ltd. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. Price momentum is positive at 79/100, suggesting the trend favors buyers. High volatility (stability score 9/100) increases portfolio risk.
In summary, Lifeward Ltd. (LFWD) earns a Reduce rating with a composite score of 33.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LFWD stock.
Related Resources for LFWD Investors
Explore more research and tools: LFWD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LFWD head-to-head with peers: LFWD vs AZN, LFWD vs SLGL, LFWD vs VMD.